Tris-Citrate/Phosphate pH 7.0 - 8.0, 0.09% Sodium Azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
1 mg/ml (Please refer to the vial label for the specific concentration.)
The epitope recognized by this antibody maps to a region between residue 75 and 125 of human p14ARF using the numbering given in entry NP_478102.1 (GeneID 1029).
Purified by antigen-affinity chromatography
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
cyclin dependent kinase inhibitor 2A , ARF , CDK4I , CDKN2 , CMM2 , INK4 , INK4A , MLM , MTS-1 , MTS1 , P14 , P14ARF , P16 , P16-INK4A , P16INK4 , P16INK4A , P19 , P19ARF , TP16
The INK4a-ARF locus is comprised of two tumor suppressors, p16INK4a and p14ARF. These two proteins are encoded through differential splicing of alternative first exons. The p16INK4a (exon 1alpha) protein inhibits the cyclin D-dependent kinases (CDK) that control the phosphorylation of the Rb protein and cell proliferation. The p14ARF gene product complexes with the MDM2 protein within the nucleus, thus modulating the activity of the p53 protein. P14ARF is a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduces growth inhibition by p14ARF.